Resetting autoimmune disease with CAR cell therapies

Area of Science:

• Immunology
• Cell Therapy
• Autoimmune Diseases

Background:

• Pathogenic B cell activation is central to many autoimmune diseases (AIDs).
• B cell depletion is a therapeutic strategy for AIDs.
• Chimeric antigen receptor (CAR) T cells, successful in cancer therapy, are being explored for AIDs treatment.

Purpose of the Study:

• To review the development of CAR-expressing cells for B cell depletion in AIDs.
• To discuss unmet needs in AIDs treatment and how CAR T cells can address them.
• To explore deep B cell depletion strategies and relevant targets.

Main Methods:

• Review of current literature on CAR T cell therapy for AIDs.
• Analysis of key targets such as CD19 and B cell maturation antigen (BCMA).
• Evaluation of autologous and allogeneic CAR T cell efficacy, safety, risks, and limitations.

Main Results:

• CAR T cells are being developed for selective B cell depletion to reset the immune system in AIDs.
• Key targets include CD19 and BCMA.
• Evidence on efficacy, safety, risks, and limitations of CAR T cells in AIDs is summarized.

Conclusions:

• CAR T cell therapy represents a rapidly advancing field for treating autoimmune diseases.
• Technological and clinical advancements are paving the way for engineered CAR-expressing cell therapies for AIDs.